Can I legally buy bremelanotide in any EU country?

No. Bremelanotide has no EMA authorisation and cannot be legally sold, prescribed, or dispensed in any EU member state. Unauthorised online vendors may appear to operate in the EU, but they do so illegally and risk enforcement action. Purchasing from them is legally risky.

What if I buy it online from outside the EU and import it?

This sits in a legal grey zone. Some EU countries permit personal imports of unlicensed medicines in small quantities under strict conditions, but customs may seize it, and legal consequences vary by member state. It is not a guaranteed safe route and carries enforcement risk.

Is there any possibility bremelanotide will be approved in the EU in the future?

It's possible but not imminent. The pharmaceutical company would need to decide to pursue EMA approval, submit an application, and undergo regulatory review—a process typically lasting 12-24 months. As of now, there is no announced plan to do so.

What are legal alternatives for low sexual desire in the EU?

Talk to your doctor about psychological interventions, lifestyle approaches, and other medications licensed in your country. Regulatory status differs by member state and indication, so your healthcare provider can guide you on available options.

Why did the US approve bremelanotide but Europe hasn't?

The pharmaceutical company pursued FDA approval first, reflecting larger market demand in the US. No formal EMA application has been submitted. European regulators also place high weight on tolerability (nausea affected 40% of trial users), which may have influenced the company's decision not to pursue European approval.

Bremelanotide Legal Status in the EU: What You Need to Know

Bremelanotide (Vyleesi) is not authorised for sale or use in the European Union. While it received FDA approval in the United States in 2019 for low sexual desire in premenopausal women, the European Medicines Agency (EMA) has not approved it, meaning it cannot be legally prescribed, dispensed, or marketed across EU member states. This jurisdictional gap is significant: EU residents interested in the treatment have no legal route to obtain it within their home countries, and importing it for personal use sits in a legal grey zone that varies by member state.

Current Legal Status in the EU

Bremelanotide has no EMA authorisation. This is the defining fact of its EU status. The European Medicines Agency, which oversees drug approval across EU member states plus Iceland, Liechtenstein, and Norway, has not granted a marketing authorisation for Vyleesi or any bremelanotide formulation.

Without EMA approval, bremelanotide cannot be:

Legally manufactured or imported for sale in the EU
Prescribed by licensed healthcare providers
Dispensed by pharmacies
Marketed or advertised to consumers

This applies uniformly across all EU member states (Germany, France, Spain, Italy, Poland, etc.), plus the European Economic Area countries. Individual member states cannot unilaterally approve medicines that lack EMA authorisation—the centralised procedure is the standard route for most active treatments.

Why Hasn't the EMA Approved It?

The absence of EMA approval reflects several dynamics:

1. No Marketing Authorisation Application (Yet) There is no public record of a formal EMA application for bremelanotide. The pharmaceutical company (Palatin Technologies, which holds the Vyleesi license) has not submitted a centralised application to the EMA. This may reflect commercial calculations: the European market for HSDD treatments is fragmented, reimbursement landscapes differ widely by country, and the modest efficacy signal from pivotal trials (approximately 25% of patients reported meaningful improvement in desire vs. 17% on placebo in two Phase 3 trials) may not justify the cost and complexity of European regulatory review.

2. Regulatory Hurdles in Europe Even if submitted, bremelanotide would face particular scrutiny in the EU:

Tolerability concerns: Nausea affected 40% of trial participants and was a primary reason for discontinuation. The EMA's Committee for Medicinal Products for Human Use (CHMP) places high weight on tolerability in indications like HSDD, where the condition itself is not life-threatening.
Modest efficacy signal: The clinical benefit over placebo, while statistically significant, is modest. European regulators tend to require a more compelling risk-benefit profile in non-urgent indications.
Long-term safety data: Concerns about permanent skin darkening with repeated use were noted in clinical trials. The EMA would likely require extended follow-up data before granting approval.

3. Market Dynamics The US market for HSDD is larger and more developed than the European market, where awareness of the condition and demand for pharmacological solutions are lower. Palatin likely prioritised FDA approval and US commercialisation.

Regulatory History

Bremelanotide's regulatory journey in the US and EU diverged sharply:

United States:

Two Phase 3 trials (MOMENT and REIGNITE-247) demonstrated efficacy and safety
FDA Fast Track designation granted in 2018, accelerating review
FDA approval granted June 2019 under the brand name Vyleesi
Market launch followed in late 2019

European Union:

No comparable development programme
No EMA submission filed
No regulatory momentum

This transatlantic divergence is typical for niche indications. The Vyleesi approval was itself considered a landmark—it was the first FDA-approved treatment specifically for low sexual desire in women—but that US success did not trigger European regulatory interest.

What Does "Not Authorised" Mean in Practice?

For EU Residents: You cannot legally obtain bremelanotide within the EU through normal channels. No licensed pharmacy will stock it; no doctor can prescribe it.

For Prescribers: EU-licensed healthcare professionals cannot legally prescribe bremelanotide. Any prescription would violate national medicines regulations in their member state.

For Importation: This is where the legal picture becomes murky. Most EU member states allow individuals to import small quantities of unlicensed medicines for personal use, provided:

The quantity is limited (typically a single course or small supply)
It is for personal, non-commercial use
The individual has a prescription from a licensed doctor (even if abroad)
Customs officers assess it as low-risk

However, the legal details vary significantly by country. Germany, for instance, permits personal imports under specific conditions; France applies stricter scrutiny. Purchasing bremelanotide from an overseas vendor and importing it carries legal risk, including potential seizure by customs, fines, or other enforcement action depending on the member state and the quantity.

No Grey-Market Regulation: Unlike some research compounds, bremelanotide is not explicitly tolerated as a research chemical in any EU jurisdiction. It is simply an unapproved medicine, subject to standard pharmaceutical enforcement.

Enforcement and Controls

EU member states enforce medicines authorisation requirements through:

National Medicines Agencies: Each country (e.g., the German Federal Institute for Drugs and Medical Devices—BfArM, the French National Agency for the Safety of Medicines—ANSM) monitors supply and can issue enforcement actions against manufacturers, importers, distributors, and retailers.

Customs and Borders: Customs authorities at EU borders, ports, and airports screen parcels and shipments. Unapproved medicines are routinely seized. The threshold for enforcement is typically low: possession of a single vial of bremelanotide for personal use could trigger seizure, though prosecution of individuals is less common than seizure of commercial shipments.

Online Pharmacy Monitoring: The EMA and member states actively monitor illegal online pharmacies. Websites selling unapproved medicines, including bremelanotide, can be reported and blocked or prosecuted.

Professional Licensing: Healthcare providers who prescribe unapproved medicines outside a strictly defined research context face disciplinary action and loss of licensure.

In practice, enforcement is concentrated on suppliers and online vendors rather than individual users, but importation of unapproved medicines remains a legal grey zone with real risks.

Comparison with Tirzepatide and Semaglutide

For context: tirzepatide and semaglutide (both approved GLP-1 receptor agonists) have full EMA authorisation for diabetes and, in semaglutide's case, weight management. This means they are legally prescribed and reimbursed across the EU. The contrast illustrates why regulatory status matters—approved compounds are integrated into healthcare systems; unapproved ones are not.

Key Takeaways for EU Residents

Bremelanotide is not legally available in the EU. There is no approved formulation, no licensed prescriber can recommend it, and no pharmacy can dispense it.
Seeking EMA approval is not currently on the regulatory roadmap. The pharmaceutical company has shown no public indication of pursuing European authorisation.
Importing it carries legal risk. While individuals in some EU countries may technically import small quantities for personal use under certain conditions, customs seizure is possible, and legal consequences vary by member state.
Alternative treatments exist. If you are interested in treatments for low sexual desire, discuss licensed options with your healthcare provider. These may include psychological interventions, hormonal approaches, and medications approved in your country.
Future approval is possible but uncertain. If clinical evidence evolves and Palatin chooses to seek EMA approval in the future, the timeline would be years away and the outcome is not guaranteed.

Understanding Medical Regulation in the EU

The EU's centralised medicines approval system is designed to ensure that only treatments with a proven safety and efficacy profile are available to patients. Bremelanotide's absence from the approved list reflects both commercial decisions and regulatory assessment. If you're considering treatment options for sexual health concerns, consulting a licensed healthcare provider in your country is the safest and most legal path forward.

Related Compounds

If you're researching peptides and regulatory status, you may also want to understand the approval landscape for Melanotan II (a related but unregulated research compound that shares bremelanotide's origins) and CJC-1295 (a growth hormone-releasing hormone analogue with similarly limited EU approvals).

Pharmacovigilance and Safety Reporting

Even though bremelanotide is not approved in the EU, adverse event reports from EU residents using it abroad are theoretically reportable to national medicines agencies. If you experience side effects from any unapproved medicine, reporting them to your national regulator can contribute to global safety surveillance.